Failure of the Nemo Trial: Bumetanide Is a Promising Agent to Treat Many Brain Disorders but Not Newborn Seizures

The diuretic bumetanide failed to treat acute seizures due to hypoxic ischemic encephalopathy (HIE) in newborn babies and was associated with hearing loss (NEMO trial, Pressler et al., 2015). On the other hand, clinical and experimental observations suggest that the diuretic might provide novel ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Ben-Ari, Yehezkel, Damier, Philippe, Lemonnier, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830840/
https://www.ncbi.nlm.nih.gov/pubmed/27147965
http://dx.doi.org/10.3389/fncel.2016.00090
_version_ 1782426957131022336
author Ben-Ari, Yehezkel
Damier, Philippe
Lemonnier, Eric
author_facet Ben-Ari, Yehezkel
Damier, Philippe
Lemonnier, Eric
author_sort Ben-Ari, Yehezkel
collection PubMed
description The diuretic bumetanide failed to treat acute seizures due to hypoxic ischemic encephalopathy (HIE) in newborn babies and was associated with hearing loss (NEMO trial, Pressler et al., 2015). On the other hand, clinical and experimental observations suggest that the diuretic might provide novel therapy for many brain disorders including Autism Spectrum Disorders (ASD), schizophrenia, Rett syndrome, and Parkinson disease. Here, we discuss the differences between the pathophysiology of severe recurrent seizures in the neonates and neurological and psychiatric disorders stressing the uniqueness of severe seizures in newborn in comparison to other disorders.
format Online
Article
Text
id pubmed-4830840
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-48308402016-05-04 Failure of the Nemo Trial: Bumetanide Is a Promising Agent to Treat Many Brain Disorders but Not Newborn Seizures Ben-Ari, Yehezkel Damier, Philippe Lemonnier, Eric Front Cell Neurosci Neuroscience The diuretic bumetanide failed to treat acute seizures due to hypoxic ischemic encephalopathy (HIE) in newborn babies and was associated with hearing loss (NEMO trial, Pressler et al., 2015). On the other hand, clinical and experimental observations suggest that the diuretic might provide novel therapy for many brain disorders including Autism Spectrum Disorders (ASD), schizophrenia, Rett syndrome, and Parkinson disease. Here, we discuss the differences between the pathophysiology of severe recurrent seizures in the neonates and neurological and psychiatric disorders stressing the uniqueness of severe seizures in newborn in comparison to other disorders. Frontiers Media S.A. 2016-04-14 /pmc/articles/PMC4830840/ /pubmed/27147965 http://dx.doi.org/10.3389/fncel.2016.00090 Text en Copyright © 2016 Ben-Ari, Damier and Lemonnier. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Ben-Ari, Yehezkel
Damier, Philippe
Lemonnier, Eric
Failure of the Nemo Trial: Bumetanide Is a Promising Agent to Treat Many Brain Disorders but Not Newborn Seizures
title Failure of the Nemo Trial: Bumetanide Is a Promising Agent to Treat Many Brain Disorders but Not Newborn Seizures
title_full Failure of the Nemo Trial: Bumetanide Is a Promising Agent to Treat Many Brain Disorders but Not Newborn Seizures
title_fullStr Failure of the Nemo Trial: Bumetanide Is a Promising Agent to Treat Many Brain Disorders but Not Newborn Seizures
title_full_unstemmed Failure of the Nemo Trial: Bumetanide Is a Promising Agent to Treat Many Brain Disorders but Not Newborn Seizures
title_short Failure of the Nemo Trial: Bumetanide Is a Promising Agent to Treat Many Brain Disorders but Not Newborn Seizures
title_sort failure of the nemo trial: bumetanide is a promising agent to treat many brain disorders but not newborn seizures
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830840/
https://www.ncbi.nlm.nih.gov/pubmed/27147965
http://dx.doi.org/10.3389/fncel.2016.00090
work_keys_str_mv AT benariyehezkel failureofthenemotrialbumetanideisapromisingagenttotreatmanybraindisordersbutnotnewbornseizures
AT damierphilippe failureofthenemotrialbumetanideisapromisingagenttotreatmanybraindisordersbutnotnewbornseizures
AT lemonniereric failureofthenemotrialbumetanideisapromisingagenttotreatmanybraindisordersbutnotnewbornseizures

Ejemplares similares